Alzheimer’s Disease is the most common cause of dementia. Dementia describing a specific set of symptoms such as memory loss, difficulties with problem-solving, language or simply thinking. As the disease progresses, proteins build up in the brain to form structures called ‘plaques’. Eventually there is a break between the nerve cells resulting the death of the cells and a loss of brain tissue. ending in a lack of motor skills. Although progression can vary, typically after diagnosis life expectancy is around three to nine years. Fewer than 3% of people live more than fourteen years.
Management
Medications, psychological intervention and care-giving are all available to AD patients. there are currently 5 different medications on offer for AD each have different results and side affects.
John Ramsay, Founder and Managing Director of Social-Ability, discusses what rising dementia cases mean for local authorities and social care spending.
Chris Lynch, Deputy CEO at Alzheimer’s Disease International, sheds light on the WHO Global action plan on the public health response to dementia 2017-2025.
Indiana University School of Medicine researchers are attempting to use magnetic nanoparticles to develop a cure for neurological disorders from epilepsy to Alzheimer's - without any invasive or genetic treatment.
Professor of Neurology Thomas Gasser, JPND’s Scientific Advisory Board Chair and Director of the Department of Neurodegenerative Diseases, shares in an interview JPND’s innovative research and collaboration efforts in the universal race against Alzheimer’s and Parkinson’s diseases.
Earlier this year, Yourgene Health entered into a collaboration with Cytox to run their genoSCORE-LAB assay in our laboratory. genoSCORE-LAB™ is a new non-invasive test that can predict the risk of an individual developing Alzheimer’s disease from a simple saliva sample.
Dr Roderick Corriveau, PhD from the National Institute of Neurological Disorders & Stroke, part of the National Institutes of Health in the U.S., details the importance of understanding the many possible paths to dementia.
Neil Wright, on behalf of McGowan Transcriptions UK, discusses the benefits of bilingualism, specifically concerning how speaking more than one language can fight dementia.
Samantha Benham-Hermetz, Director of Policy and Public Affairs at Alzheimer’s Research UK charts us through the priorities for dementia research in the UK in light of COVID-19.
Daniel Berman from Nesta Challenges and Colin Capper at the Alzheimer’s Society focus here on dementia tech, including comment on overcoming barriers to innovation post-pandemic.
